P2RY12 and chronic kidney disease: The final cohort comprised 55,349 patients with incident CKD who received P2Y12-Is: 96.7% of the patients were in the clopidogrel group (n=53,524) and the remaining 3.3% of patients were in the prasugrel or ticagrelor group (n=1825) (Supplemental Figure 1).